FDA approval of semaglutide could help Novo Nordisk access unexploited obesity market

Before the end of the week, the FDA will reveal its verdict on Novo Nordisk's obesity treatment semaglutide. According to Sydbank analyst Søren Løntoft Hansen, this is a crucial approval for the Danish pharmaceutical company.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde

On Friday at the latest, the US Food and Drug Administration (FDA) will decide whether to approve Novo Nordisk's molecule semaglutide for treating obesity.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading